Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
As new therapies emerge, clinicians face a critical question: which modern therapy offers the best outcomesGLP-1 agonists or SGLT2 inhibitors
This represents a clinically meaningful change in cardiovascular and metabolic risk
Inzucchi SE, Iliev H, Pfarr E, Zinman B (2018) Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME Trial
Healthy fats Fat gets a bad rap, but not all types of dietary fat are the same
Cons: Requires finding a qualified provider, insurance may not cover it, no pre-made food included
Not every patient is a candidate for GLP-1 medication, and that is not a dead end
US$ 27.48
US$ 26.16
US$ 25.09
US$ 27.58
US$ 28.99
US$ 29.40
US$ 24.32
US$ 29.34
US$ 22.44
US$ 21.82
.webp)
US$ 23.23
US$ 20.60
US$ 28.19
